InMed Pharmaceuticals (TSE:IN) Commercial-Scale Cannabinoid Manufacturing

On Nov 28, 2020

4InMed Pharmaceuticals Inc (TSE:IN) (OTCMKTS:IMLFF) (FRA:MWG2) is using biosynthesized cannabinoids for medical research. While most companies developing synthetic cannabinoids use yeast, InMed is the only company in the world using e coli in its fermentation process. CBO Josh Blacher shares details of the company’s development of a treatment for Epidermolysis bullosa or EB, a serious genetic condition with no current approved treatment. Blacher believes InMed is about a year away from Phase I clinical trials for its EB treatment and hopes the treatment will be on the market by 2022. Blacher discusses the advantages and cost savings of synthetic cannabinoids and believes all cannabis derivative products could soon be made from synthetic ingredients.

************************

Check out our website:
https://midasletter.com

************************

SUBSCRIBE to our YouTube:
http://bit.ly/MidasLetterYoutube

SUBSCRIBE to our Newsletter:
http://bit.ly/MidasLetterNewsletter

Download Our Podcast on iTunes:
http://bit.ly/MidasLetterPodcast

************************

Like Us on Instagram:
http://bit.ly/MidasLetterInsta

Like Us on Facebook:
http://bit.ly/MidasLetterFacebook

************************

#
#
#MidasLetter

source